Compare WST & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | GH |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9B | 22.9B |
| IPO Year | 2004 | 2018 |
| Metric | WST | GH |
|---|---|---|
| Price | $414.40 | $155.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 26 |
| Target Price | ★ $471.00 | $200.88 |
| AVG Volume (30 Days) | 690.9K | ★ 2.0M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | 1.49 | ★ 6.74 |
| EPS | ★ 7.09 | N/A |
| Revenue | ★ $2,886,900,000.00 | $982,021,000.00 |
| Revenue This Year | $11.26 | $39.22 |
| Revenue Next Year | $5.92 | $35.02 |
| P/E Ratio | $58.45 | ★ N/A |
| Revenue Growth | 1.95 | ★ 32.88 |
| 52 Week Low | $223.83 | $74.55 |
| 52 Week High | $438.27 | $191.05 |
| Indicator | WST | GH |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 41.68 |
| Support Level | $326.40 | $154.16 |
| Resistance Level | $438.27 | $177.55 |
| Average True Range (ATR) | 11.68 | 10.26 |
| MACD | -0.14 | -2.09 |
| Stochastic Oscillator | 52.87 | 39.85 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.